Table 1.
Patient characteristics.
| Demographics (n = 170) | |
| Age in years, median (IQR) | 56.0 (53.6–58.4) |
| Male, n (%) | 110 (64.7) |
| Weight in kg, mean ± SD | 75 ± 19 |
| Height in cm, median (IQR) | 170 (165–178) |
| Body surface area in m2, median (IQR) | 1.9 (1.7–2.0) |
| Body mass index in kg/m2, median (IQR) | 25.4 (22.0–27.8) |
| Severity scores | |
| SAPS-2 score at ICU admission, median (IQR) | 39 (38.5–51) |
| Modified SOFA score at day 1, median (IQR) | 4 (2–5) |
| Renal replacement therapy, n (%) | 12 (6) |
| Extra corporeal life support, n (%) | 6 (3) |
| Biological data at day 0 (n = 196), median (IQR) | |
| Hematocrit in % | 29 (26–34) |
| Serum albumin in g/L | 29 (25–33) |
| Serum creatinine in μmol/L | 65 (48–104) |
| Indexed creatinine clearance in mL/min/1.73 m2 | 71.4 (31.5–111.0) |
| Infection (n = 196) | |
| Documented, n (%) | 136 (69.4) |
| Respiratory tract | 70 (51.5) |
| Primary bacteremia | 35 (25.7) |
| Urinary tract | 21 (15.5) |
| Intra-abdominal | 1 (0.7) |
| Central nervous system | 3 (2.2) |
| Other sites | 6 (4.4) |
| Not documented, n (%) | 60 (30.6) |
| Antibiotic treatments (n = 196) | |
| Empirical treatment, n (%) | |
| Cefotaxime | 80 (40.8) |
| Cefepime | 45 (23.0) |
| Ceftazidime | 41 (20.9) |
| Meropenem | 30 (15.3) |
| Duration of antibiotic therapy in days, median (IQR) | 7 (5–10) |
| Outcome (n = 170) | |
| Length of ICU stay in days, median (IQR) | 33 (17–67) |
| Alive at day 28, n (%) | 143 (84.1) |
Data are number (%) or median (inter-quartile range). SAPS-2, Simplified Acute Physiology Score 2; SOFA, Sepsis-related Organ Failure Assessment.